Clinical trials: Lymphoma, Hodgkins
Non Hodgkin Lymphoma
GVM±R in Patients With Relapsed or Refractory Aggressive NHL
This is a prospective, dose-escalation clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT05299164
- Testing
- Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level 2, Liposomal Mitoxantrone Hydrochloride dose level 3
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
The overall goal of this clinical research study was to find out which of two different chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective in treating B-cell lymphoma.
- Trial name
- NCT00290498
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005998
- Testing
- carmustine, cyclophosphamide, cytarabine
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT07097363
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Non-Hodgkin's Lymphoma, Multiple
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Lymphoma
- Trial name
- NCT01609816
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non Hodgkin Lymphoma
Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Current therapies for Non-Hodgkin's Lymphoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Non-Hodgkin's Lymphoma.
- Trial name
- NCT00003498
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Burzynski Research Institute
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Hodgkin Lymphoma, Hepatitis B Reactivation
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
- Trial name
- NCT01914744
- Testing
- Entecavir, Lamivudine
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fudan University
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
RATIONALE: Monoclonal antibodies such as anti-cytotoxic T-lymphocyte-associated antigen-4 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00047164
- Testing
- ipilimumab
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphoma
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of carfilzomib that can be given in combination with lenalidomide and rituximab to patients with relapsed or refractory B-cell non-hodgkin…
- Trial name
- NCT01729104
- Testing
- Carfilzomib, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00030849
- Testing
- recombinant interferon alfa, bexarotene
- Where
- 5 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
NHL, Multiple Myeloma
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without…
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
- Trial name
- NCT06119685
- Testing
- IDP-023, Rituximab, Daratumumab
- Where
- 12 sites in United States
- Volunteers
- 128 people
- Sponsor
- Indapta Therapeutics, INC.
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
This study is for patients with lymphoproliferative malignancies that have progressed after receiving a previous treatment (relapsed) or are no longer responding to treatment (refractory).
- Conditions
- Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma
- Trial name
- NCT00481871
- Testing
- Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12
- Where
- 15 sites in United States
- Volunteers
- 119 people
- Sponsor
- Acrotech Biopharma Inc.
Hodgkin Disease Lymphoma
Sperm Epigenome in Hodgkin Lymphoma
Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only…
- Trial name
- SPELH (NCT07449832)
- Testing
- Additional semen samples
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Lymphoma
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00233987
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 53 sites in United States
- Volunteers
- 98 people
- Sponsor
- SWOG Cancer Research Network
Diffuse Large B Cell Lymphoma, Peripheral T Cell Lymphoma
Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients
The purpose of this study is to evaluate the effectiveness of circulating DNA from peripheral blood for predicting the prognosis and relapse in DLBCL and PTCL patients.
- Trial name
- NCT03079947
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Peripheral T-cell Lymphoma
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.
- Trial name
- COMPLETE (NCT01110733)
- Where
- 68 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Acrotech Biopharma Inc.
Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39P, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
- Trial name
- NCT06295549
- Testing
- LUCAR-G39P cells product
- Where
- 3 sites in China
- Volunteers
- 11 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lymphoma
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009776
- Testing
- monoclonal antibody Lym-1, cyclosporine, paclitaxel
- Where
- United States
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.